Verona Pharma provided a positive update on 7 November highlighting a busy few months and patient enrolment in the Phase IIb trial progressing ahead of schedule (top line data now expected mid-2018). We update forecasts this morning to reflect some R&D expenditure being brought forward as a result. The group’s balance sheet remains strong with £85.5m as at 30 September 2017, providing the group with sufficient funds to progress RPL554 to a number of inflection points. We look forward to the Phas ....
27 Nov 2017
N+1 Singer - Verona Pharma - Two important readouts in 2018
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - Verona Pharma - Two important readouts in 2018
Verona Pharma plc Sponsored ADR (VRNA:NAS) | 0 0 0.0%
- Published:
27 Nov 2017 -
Author:
Sheena Berry -
Pages:
3
Verona Pharma provided a positive update on 7 November highlighting a busy few months and patient enrolment in the Phase IIb trial progressing ahead of schedule (top line data now expected mid-2018). We update forecasts this morning to reflect some R&D expenditure being brought forward as a result. The group’s balance sheet remains strong with £85.5m as at 30 September 2017, providing the group with sufficient funds to progress RPL554 to a number of inflection points. We look forward to the Phas ....